BioCentury
ARTICLE | Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

November 16, 2018 3:58 PM UTC

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million ($32.9 million). Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund co-led with participation from VI Partners, Schroder Adveq and High-Tech Gründerfonds; all investors are returning...